Hospital
Trident Medical Center, LLC
Trident Medical Center, LLC was paid $55.82M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoTRIDENT MEDICAL CENTER, LLC
CHARLESTON, SC 29406
CHARLESTON, SC 29406
33aNPI1366496937assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$55.82M
24GClaims1,699,344
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#7 of 115
Median peer was paid$2.47M
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 199,345 | $7.11M | |
| 2019 | 209,949 | $6.74M | |
| 2020 | 210,047 | $6.06M | |
| 2021 | 287,872 | $8.71M | |
| 2022 | 291,643 | $10.21M | |
| 2023 | 266,436 | $10.27M | |
| 2024incomplete | 234,052 | $6.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 146,072 | 135,274 | $7.01M |
| 80053 | Comprehensive metabolic panel | 9.6% | 62,296 | 54,622 | $5.36M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.1% | 17,251 | 16,481 | $3.42M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 5.8% | 7,885 | 6,994 | $3.24M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.7% | 33,581 | 28,414 | $2.62M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 44,083 | 42,351 | $2.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.5% | 80,060 | 71,257 | $1.95M |
| 87081 | 3.0% | 21,661 | 21,125 | $1.66M | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 2.7% | 4,108 | 3,941 | $1.50M |
| 36415 | Collection of venous blood by venipuncture | 2.4% | 7,291 | 6,947 | $1.33M |
| 87275 | 2.3% | 26,574 | 25,690 | $1.31M | |
| 81001 | 2.2% | 68,763 | 62,441 | $1.25M |
323 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 12,947 | $1.23M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.5% | 8,124 | $837K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 20,799 | $718K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.2% | 5,445 | $682K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 21,326 | $673K |
| 87210 | 1.1% | 6,808 | $599K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,034 | $548K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,870 | $528K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19,829 | $527K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,912 | $492K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 44,939 | $470K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,373 | $413K |
| 81025 | <1% | 41,698 | $396K | |
| 12001 | <1% | 2,111 | $371K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,299 | $368K |
| 81002 | <1% | 2,904 | $355K | |
| 12011 | <1% | 1,821 | $353K | |
| 71045 | Radiologic examination, chest; single view | <1% | 30,400 | $330K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 34,019 | $326K |
| 10060 | <1% | 1,897 | $313K | |
| 73610 | <1% | 4,089 | $309K | |
| 74018 | <1% | 4,033 | $306K | |
| 99285 | Emergency room visit (most serious) | <1% | 16,467 | $304K |
| 73562 | <1% | 5,405 | $303K | |
| 73130 | <1% | 4,060 | $298K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12,109 | $295K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,708 | $290K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,902 | $275K |
| 73630 | <1% | 4,784 | $272K | |
| 82565 | <1% | 1,423 | $263K | |
| J3490 | Unclassified drugs | <1% | 2,206 | $249K |
| 84702 | <1% | 6,169 | $249K | |
| 84112 | <1% | 1,060 | $247K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,208 | $236K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,467 | $232K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 828 | $220K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,330 | $206K |
| 73030 | <1% | 3,867 | $195K | |
| 73140 | <1% | 1,842 | $195K | |
| 76801 | <1% | 3,488 | $178K | |
| 73110 | <1% | 2,841 | $175K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,179 | $171K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,607 | $170K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,748 | $169K |
| 85027 | <1% | 97,750 | $168K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 20,556 | $167K |
| 72100 | <1% | 4,125 | $165K | |
| 84484 | <1% | 27,924 | $164K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,234 | $155K |
| 74019 | <1% | 2,592 | $151K | |
| 87070 | <1% | 1,794 | $150K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,741 | $145K |
| 76825 | <1% | 845 | $143K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,994 | $136K |
| 76642 | <1% | 1,741 | $121K | |
| 87420 | <1% | 3,963 | $117K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 119 | $111K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,554 | $110K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,743 | $110K |
| 87077 | <1% | 4,290 | $110K | |
| 93971 | <1% | 2,582 | $108K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,733 | $106K |
| 72050 | <1% | 1,490 | $105K | |
| 12002 | <1% | 712 | $99K | |
| 73080 | <1% | 1,887 | $98K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,715 | $96K |
| 80047 | <1% | 1,183 | $95K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,024 | $95K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,504 | $93K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,144 | $91K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 10,818 | $91K |
| 76820 | <1% | 1,790 | $91K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,405 | $90K |
| 73090 | <1% | 1,744 | $87K | |
| 15853 | <1% | 228 | $86K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 685 | $82K |
| 73502 | <1% | 1,801 | $73K | |
| 72072 | <1% | 1,592 | $72K | |
| G0378 | Hospital observation service, per hour | <1% | 8,822 | $70K |
| 76770 | <1% | 939 | $69K | |
| 73590 | <1% | 1,773 | $66K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,056 | $63K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,639 | $60K |
| 80076 | <1% | 1,997 | $59K | |
| 81003 | <1% | 4,255 | $58K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,865 | $57K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,330 | $57K |
| 29125 | <1% | 925 | $56K | |
| 84703 | <1% | 8,282 | $52K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 455 | $51K |
| 16020 | <1% | 661 | $50K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,953 | $50K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 396 | $44K |
| 82731 | <1% | 225 | $44K | |
| 71250 | <1% | 501 | $43K | |
| 86850 | <1% | 3,319 | $42K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 279 | $40K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,649 | $38K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 425 | $37K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,925 | $36K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,040 | $35K |
| 77336 | <1% | 403 | $35K | |
| 99152 | <1% | 819 | $35K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,991 | $34K |
| 70486 | <1% | 1,225 | $32K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 42,550 | $32K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,158 | $32K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,520 | $27K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 174 | $26K |
| 93970 | <1% | 605 | $26K | |
| 72131 | <1% | 741 | $24K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,520 | $24K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,389 | $23K |
| 71101 | <1% | 367 | $23K | |
| 82247 | <1% | 1,224 | $22K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 102 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,315 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,697 | $20K |
| 77065 | Tomosynthesis, mammo | <1% | 565 | $19K |
| 83880 | <1% | 6,818 | $19K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,174 | $18K |
| 85007 | <1% | 774 | $17K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,297 | $17K |
| 80061 | Lipid panel | <1% | 5,095 | $16K |
| 70360 | <1% | 161 | $16K | |
| 72040 | <1% | 188 | $16K | |
| 73660 | <1% | 161 | $15K | |
| A9270 | Non-covered item or service | <1% | 11,323 | $15K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,172 | $15K |
| 82607 | <1% | 1,041 | $13K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,809 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,285 | $12K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,541 | $12K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,967 | $12K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $12K |
| 70496 | <1% | 642 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,827 | $12K |
| 36600 | <1% | 142 | $11K | |
| 84439 | <1% | 3,097 | $11K | |
| 73552 | <1% | 323 | $10K | |
| 88304 | <1% | 1,371 | $10K | |
| 97161 | <1% | 587 | $10K | |
| 83605 | <1% | 4,697 | $9K | |
| 82570 | <1% | 1,085 | $9K | |
| 83690 | <1% | 21,781 | $9K | |
| 86140 | <1% | 1,779 | $9K | |
| 70498 | <1% | 741 | $9K | |
| 85379 | <1% | 5,380 | $9K | |
| C1769 | Guide wire | <1% | 1,132 | $9K |
| 84156 | <1% | 967 | $9K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,019 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,528 | $8K |
| 73060 | <1% | 227 | $8K | |
| 88307 | <1% | 596 | $8K | |
| 82270 | <1% | 112 | $8K | |
| 76870 | <1% | 143 | $8K | |
| 74174 | <1% | 124 | $8K | |
| 97162 | <1% | 1,025 | $8K | |
| 96376 | <1% | 3,131 | $8K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,384 | $7K |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 4,150 | $7K |
| 82728 | <1% | 1,118 | $7K | |
| 86592 | <1% | 173 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,588 | $7K |
| 86900 | <1% | 5,508 | $7K | |
| 85610 | <1% | 7,999 | $7K | |
| 73600 | <1% | 111 | $7K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 185 | $6K |
| 70491 | <1% | 269 | $6K | |
| 93922 | <1% | 25 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 104 | $6K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 894 | $6K |
| 93017 | <1% | 521 | $6K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 94 | $6K |
| 29515 | <1% | 149 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,815 | $5K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 173 | $5K |
| 74022 | <1% | 253 | $5K | |
| 84100 | <1% | 3,169 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 29 | $5K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $5K |
| 74246 | <1% | 93 | $4K | |
| 97116 | <1% | 184 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 387 | $4K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 530 | $4K |
| 87186 | <1% | 4,139 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 463 | $4K |
| 69200 | <1% | 24 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 119 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,710 | $3K |
| 73620 | <1% | 57 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 518 | $3K |
| 82330 | <1% | 246 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,632 | $3K |
| 73560 | <1% | 79 | $3K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 105 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 47 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,989 | $2K |
| 00731 | <1% | 444 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $2K |
| 83735 | <1% | 12,421 | $2K | |
| 86308 | <1% | 78 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,999 | $2K |
| 87276 | <1% | 26,576 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 79 | $2K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 10,378 | $2K |
| 86141 | <1% | 254 | $2K | |
| 86780 | <1% | 103 | $2K | |
| 72170 | <1% | 58 | $2K | |
| 82784 | <1% | 164 | $2K | |
| 83540 | <1% | 1,015 | $2K | |
| 85018 | <1% | 1,282 | $2K | |
| 80164 | <1% | 478 | $2K | |
| 97166 | <1% | 222 | $2K | |
| 87040 | <1% | 4,023 | $2K | |
| 72128 | <1% | 38 | $1K | |
| 86701 | <1% | 65 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,796 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 174 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 117 | $1K |
| 85014 | <1% | 862 | $1K | |
| 11045 | <1% | 1,807 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 84 | $1K |
| 93325 | <1% | 951 | $1K | |
| 85046 | <1% | 1,367 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 19 | $1K |
| 86703 | <1% | 268 | $1K | |
| 82803 | <1% | 399 | $1K | |
| 77080 | <1% | 12 | $972.40 | |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 252 | $966.93 |
| 97597 | <1% | 263 | $916.12 | |
| 36000 | <1% | 325 | $892.46 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,747 | $859.85 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 88 | $801.60 |
| 82150 | <1% | 445 | $754.35 | |
| 11043 | <1% | 39 | $673.30 | |
| 85730 | <1% | 6,125 | $669.38 | |
| 82950 | <1% | 27 | $619.64 | |
| 83655 | <1% | 42 | $614.05 | |
| 82248 | <1% | 2,352 | $593.69 | |
| 97165 | <1% | 56 | $552.55 | |
| 90714 | <1% | 2,601 | $550.98 | |
| 87147 | <1% | 2,973 | $509.31 | |
| 86038 | <1% | 13 | $454.00 | |
| 87205 | <1% | 2,425 | $452.86 | |
| 84550 | <1% | 575 | $418.59 | |
| 84132 | <1% | 269 | $349.81 | |
| 85651 | <1% | 2,193 | $322.82 | |
| 83993 | <1% | 26 | $318.89 | |
| 73521 | <1% | 12 | $308.86 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,823 | $297.16 |
| 82746 | <1% | 142 | $252.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,719 | $236.64 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 585 | $226.11 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,268 | $189.01 |
| 00840 | <1% | 366 | $171.24 | |
| 82550 | <1% | 2,282 | $170.69 | |
| 94644 | <1% | 202 | $131.72 | |
| 88302 | <1% | 12 | $113.84 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 322 | $80.85 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 871 | $68.91 |
| 86901 | <1% | 5,500 | $68.12 | |
| 94664 | <1% | 147 | $51.56 | |
| 86803 | <1% | 13 | $39.73 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 770 | $24.16 |
| 86920 | <1% | 188 | $24.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 130 | $15.64 |
| 82553 | <1% | 318 | $14.39 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 338 | $1.98 |
| 90686 | 0% | 13 | $0.00 | |
| 88342 | 0% | 551 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 243 | $0.00 |
| 84153 | 0% | 13 | $0.00 | |
| 86762 | 0% | 30 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 35 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 123 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 367 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 17 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 18 | $0.00 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 20 | $0.00 |
| 83921 | 0% | 24 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 41 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 131 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 27 | $0.00 |
| 87340 | 0% | 76 | $0.00 | |
| 00790 | 0% | 42 | $0.00 | |
| 00813 | 0% | 51 | $0.00 | |
| Q4100 | Skin substitute, not otherwise specified | 0% | 26 | $0.00 |
| 41899 | Unlisted procedure, dentoalveolar structures | 0% | 53 | $0.00 |
| 86364 | 0% | 38 | $0.00 | |
| 82043 | 0% | 12 | $0.00 | |
| 36430 | 0% | 20 | $0.00 | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 0% | 14 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 20 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 502 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 150 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 251 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 60 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 381 | $0.00 |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 155 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 131 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 40 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 14 | $0.00 |
| 84450 | 0% | 56 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 96 | $0.00 |
| 47562 | 0% | 28 | $0.00 | |
| 84460 | 0% | 57 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 18 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 79 | $0.00 |
| 83516 | 0% | 68 | $0.00 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 91 | $0.00 |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | 0% | 12 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 29 | $0.00 |
| 82010 | 0% | 38 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 14 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 183 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 17 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 12 | $0.00 |
| 83970 | 0% | 13 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 15 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 15 | $0.00 |
| 0042T | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKEOWN, KEVIN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Trident Medical Center LLC | North Charleston, SC | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.